Federation des caisses Desjardins du Quebec’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39.6M | Buy |
209,951
+41,941
| +25% | +$7.89M | 0.12% | 131 |
|
|
2026
Q1 | $32.6M | Buy |
168,010
+80,973
| +93% | +$15.6M | 0.12% | 139 |
|
|
2025
Q4 | $16M | Sell |
87,037
-1,605
| -2% | -$281K | 0.06% | 214 |
|
|
2025
Q3 | $13.6M | Buy |
88,642
+2,690
| +3% | +$407K | 0.05% | 226 |
|
|
2025
Q2 | $12M | Sell |
85,952
-29,352
| -25% | -$4.11M | 0.05% | 227 |
|
|
2025
Q1 | $16.9M | Buy |
115,304
+7,777
| +7% | +$1.13M | 0.08% | 169 |
|
|
2024
Q4 | $14.1M | Sell |
107,527
-8,090
| -7% | -$1.13M | 0.07% | 193 |
|
|
2024
Q3 | $18M | Buy |
115,617
+63,125
| +120% | +$10.2M | 0.09% | 164 |
|
|
2024
Q2 | $8.19M | Buy |
52,492
+38,824
| +284% | +$5.84M | 0.04% | 230 |
|
|
2024
Q1 | $1.85M | Buy |
13,668
+6,366
| +87% | +$843K | 0.01% | 545 |
|
|
2023
Q4 | $984K | Buy |
7,302
+3,969
| +119% | +$516K | 0.01% | 642 |
|
|
2023
Q3 | $451K | Buy |
3,333
+147
| +5% | +$20.1K | ﹤0.01% | 771 |
|
|
2023
Q2 | $456K | Buy |
3,186
+276
| +9% | +$40.6K | ﹤0.01% | 781 |
|
|
2023
Q1 | $404K | Sell |
2,910
-273
| -9% | -$36.7K | ﹤0.01% | 790 |
|
|
2022
Q4 | $432K | Buy |
3,183
+308
| +11% | +$38.6K | 0.01% | 792 |
|
|
2022
Q3 | $315K | Sell |
2,875
-37
| -1% | -$4.69K | ﹤0.01% | 912 |
|
|
2022
Q2 | $385K | Sell |
2,912
-315
| -10% | -$41.3K | ﹤0.01% | 871 |
|
|
2022
Q1 | $428K | Sell |
3,227
-525
| -14% | -$63K | ﹤0.01% | 895 |
|
|
2021
Q4 | $437K | Sell |
3,752
-314
| -8% | -$36.9K | ﹤0.01% | 888 |
|
|
2021
Q3 | $488K | Sell |
4,066
-1,522
| -27% | -$177K | 0.01% | 877 |
|
|
2021
Q2 | $669K | Sell |
5,588
-921
| -14% | -$101K | 0.01% | 806 |
|
|
2021
Q1 | $647K | Sell |
6,509
-1,455
| -18% | -$146K | 0.01% | 778 |
|
|
2020
Q4 | $796K | Buy |
7,964
+3,170
| +66% | +$336K | 0.01% | 685 |
|
|
2020
Q3 | $525K | Buy |
4,794
+902
| +23% | +$100K | 0.01% | 661 |
|
|
2020
Q2 | $412K | Buy |
3,892
+1,071
| +38% | +$111K | 0.01% | 690 |
|
|
2020
Q1 | $252K | Sell |
2,821
-182
| -6% | -$17.1K | ﹤0.01% | 806 |
|
|
2019
Q4 | $299K | Sell |
3,003
-210
| -7% | -$19.8K | ﹤0.01% | 929 |
|
|
2019
Q3 | $286K | Sell |
3,213
-472
| -13% | -$40.9K | ﹤0.01% | 937 |
|
|
2019
Q2 | $304K | Sell |
3,685
-415
| -10% | -$32.5K | ﹤0.01% | 910 |
|
|
2019
Q1 | $332K | Sell |
4,100
-91,417
| -96% | -$7.21M | 0.01% | 828 |
|
|
2018
Q4 | $7.26M | Sell |
95,517
-2,508
| -3% | -$196K | 0.12% | 151 |
|
|
2018
Q3 | $7.76M | Sell |
98,025
-702
| -0.7% | -$53.1K | 0.11% | 165 |
|
|
2018
Q2 | $6.93M | Buy |
98,727
+1,220
| +1% | +$87.8K | 0.1% | 178 |
|
|
2018
Q1 | $6.82M | Buy |
97,507
+2,250
| +2% | +$156K | 0.11% | 181 |
|
|
2017
Q4 | $6.61M | Buy |
95,257
+1,225
| +1% | +$82.6K | 0.1% | 186 |
|
|
2017
Q3 | $6.37M | Buy |
94,032
+6,085
| +7% | +$384K | 0.1% | 187 |
|
|
2017
Q2 | $6M | Buy |
87,947
+3,790
| +5% | +$248K | 0.1% | 191 |
|
|
2017
Q1 | $5.24M | Buy |
+84,157
| New | +$4.9M | 0.1% | 179 |
|
Other funds holding AZN
EP
IA
Federation des caisses Desjardins du Quebec's AZN Position: Q2 2026 in Review
Federation des caisses Desjardins du Quebec increased its AstraZeneca (AZN) stake by 25% in Q2 2026, buying an estimated $7.89M and bringing the position to 209,951 shares worth $39.6M. The position accounts for 0.12% of the portfolio, ranked #131.
Federation des caisses Desjardins du Quebec first reported a position in AZN in Q1 2017 and has held it in 38 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Federation des caisses Desjardins du Quebec held 209,951 shares of AstraZeneca worth $39.6M as of Q2 2026.
- Federation des caisses Desjardins du Quebec bought 41,941 AstraZeneca shares in Q2 2026, an estimated $7.89M.
- AstraZeneca made up 0.12% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #131 holding.
- Federation des caisses Desjardins du Quebec first reported a position in AstraZeneca in Q1 2017 and has held it in 38 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.